Maged El-Zein, MD
Pulmonary Disease · Wichita, KSNPI 1548261415
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,031, 2.9 times the $359 reported in 2019.
Across 178 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$623
- Sanofi$538
- AstraZeneca$484
- Genentech USA, Inc.$295
- Regeneron Healthcare Solutions, Inc.$193
- Actelion Pharmaceuticals US, Inc.$185
- plus $1K from 27 others
What the payments were for
- Consulting fees$170%
- Food & beverage$3,45896%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $623 |
| Sanofi | 22 | $538 |
| AstraZeneca | 28 | $484 |
| Genentech USA, Inc. | 16 | $295 |
| Regeneron Healthcare Solutions, Inc. | 4 | $193 |
| Actelion Pharmaceuticals US, Inc. | 7 | $185 |
| Grifols USA, LLC | 8 | $172 |
| Abiomed | 1 | $124 |
| Boehringer Ingelheim | 4 | $75 |
| Harmony Biosciences LLC | 4 | $74 |
| Electromed, Inc. | 3 | $58 |
| Inspire Medical Systems, Inc. | 3 | $55 |
| Veran Medical Technologies, Inc. | 1 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Merck | 3 | $53 |
| Insmed, Inc. | 3 | $52 |
| United Therapeutics Corporation | 3 | $46 |
| Amgen | 2 | $45 |
| Apria Healthcare LLC | 2 | $44 |
| AbbVie(2 entities) | 3 | $44 |
| Novartis | 3 | $38 |
| Resmed Corp | 2 | $37 |
| Vifor Pharma, Inc. | 1 | $35 |
| Lilly USA, LLC | 2 | $33 |
| 3b Medical, Inc. | 2 | $25 |
| Johnson & Johnson | 1 | $22 |
| Gilead | 1 | $20 |
| Vapotherm Inc | 1 | $18 |
| Hospira, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Itamar Medical Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,586 in reported general payments places this provider in the 60th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 25 | $425,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 524 | $391,095 |
| OfevNintedanib Esylate | 17 | $191,961 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $171,185 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 259 | $168,984 |
| Breo ElliptaFluticasone/Vilanterol | 218 | $94,869 |
| WakixPitolisant Hcl | 12 | $88,046 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 108 | $55,854 |
| Spiriva RespimatTiotropium Bromide | 66 | $40,793 |
| Incruse ElliptaUmeclidinium Bromide | 55 | $24,806 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 38 | $22,934 |
| Advair HfaFluticasone Propion/Salmeterol | 72 | $21,868 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $18,751 |
| AdderallDextroamphetamine/Amphetamine | 12 | $16,842 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 93 | $15,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $623 | $581,555961 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $75 | $274,438161 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $484 | $184,045320 claims |
| Grifols USA, LLCProlastin C | $172 | $171,18512 claims |
| Harmony Biosciences LLCWakix | $74 | $88,04612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $17 | $16,84212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Nader EldikaWichita$9K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.